丁酸梭菌

丁酸梭菌又稱丁酸菌、酪酸梭菌、酪酸菌、宮入菌。梭菌目梭菌科梭菌屬的一種細菌。歷史.是一種梭狀芽孢桿菌，也稱丁酸菌，在細菌學分類上歸屬於梭菌屬。1933年由日本千葉醫科大學宮入近治博士首先發現並報告的，因此，又名宮入菌(MIYAIRI 588株)。功能.酪酸菌為人體腸道正常菌群之一，約有700多株，其中安全性高且具有治療效果的菌株編號為第588株，稱為宮入菌(CBM 588)，其能代謝腸道內的植物纖維而產生短鏈脂肪酸。能透過胃酸、腸液和膽汁，具有抑制多種致病菌生長和繁殖，促進結腸上皮細胞增殖，有利於損傷上皮的修復，平衡腸道菌叢生態等功能。酪酸菌在日本、韓國以及中國等亞洲國家和地區已被廣泛用於防治腸道菌群失調所致的急慢性腹瀉、抗生素相關性腸炎、便秘或腹瀉便秘交替症、胃十二指腸潰瘍合併幽門螺旋桿菌感染、過敏性腸易激綜合症狀(IBS)等疾病、免疫調節以及癌症輔助治療，療效良好。實驗• 酪酸菌調節腸道平衡,改善慢性腸道炎症(IBD )Probiotics "Clostridium butyricum" and Bacillus subtilis ameliorate intestinaltumorigenesis. J Gastroenterol (2015) 50:928–939• 酪酸菌代謝物丁酸鹽可降低脂肪生成"Clostridium butyricum" reduce lipogenesis through bacterial wall components andbutyrate.Appl Microbiol Biotechnol (2014) 98:7549–7557• 酪酸菌和枯草芽孢桿菌抑制直腸癌細胞增殖,促進腫瘤細胞凋亡Probiotics "Clostridium butyricum" and "Bacillus subtilis" ameliorate intestinaltumorigenesis. Future Microbiology, Vol.10(9)(2015),1433‐1445• 酪酸菌抑制膀胱癌"Clostridium butyricum" MIYAIRI 588 shows antitumor effects by enhancing therelease of TRAIL from neutrophils through MMP‐8 ,Int. J of oncology ,42: 903‐911, 2013• 酪酸菌治療腸內有害菌群引起之免疫失調疾病Implication of Harmful Intestinal Microflora in the Pathogenesis of Disease with Immune Dysfunction Bioscience microflora vol.17 (1) 55~60, 1998• 酪酸菌 Clostridium butyricum MIYAIRI 588(CBM 588) 抑制白色念珠菌增強免疫系統之胞殺及吞噬作用Protection Activity Induced by the Bacterial Vaccine, Heat-Killed "Clostridium butyricum" Against "Candida albicans" Infections in Mice Volume 28, Issue 2 , 262-269, 1987• 酪酸菌抑制腸炎和過敏癥的可能性-腸內細菌誘導免疫調節蛋白和免疫調節細胞，具有腸道免疫保持恆常性的機轉Smad2 and Smad3 Inversely Regulate TGF-β Autoinduction in "Clostridium butyricum"-Activated Dendritic CellsKashiwagi, Ikkou et al.Immunity , Volume 43 , Issue 1 , 65-79 ,2015• 酪酸益生菌 宮入菌 "Clostridium butyricum" MIYAIRI 588(CBM 588)腎臟病可增加兒童原發性腎病症候群(INS)患者體內產酪酸的腸道菌和血液Treg數量，減少INS患者的復發頻率及降低對免疫抑製劑的需要。Clinical Significance of Probiotics for Children with Idiopathic Nephrotic Syndrome Nutrients, 13(2), 365, 2021• 酪酸益生菌 宮入菌 "Clostridium butyricum" MIYAIRI 588(CBM 588)作為治療耐藥性抑鬱症的輔助治療"Clostridium butyricum" MIYAIRI 588 as Adjunctive Therapy for Treatment-Resistant Major Depressive Disorder:A Prospective Open-Label TrialTsuyoshi Miyaoka, MD, PhD, Clinical Neuropharmacology, Volume 41, Number 5, September/October 2018, 151-115• 酪酸菌 "Clostridium butyricum" MIYAIRI 588(CBM 588)與免疫檢查點抑制劑(ICB)合併使用，提高非小細胞肺癌患者存活率Association of Probiotic Clostridium butyricum Therapy with Survival and Response to Immune Checkpoint Blockade in Patients with Lung Cancer Cancer Immunol Res (2020) 8 (10): 1236–1242.• 酪酸益生菌 宮入菌 "Clostridium butyricum" MIYAIRI 588(CBM 588)可增強術前化療的胰腺癌患者抗癌免疫力Intestinal Care Using L‒Glutamine Supplement and Probiotics Can Induce a Strong Anti‒Tumor Immune Response through the Induction of Mature Tertiary Lymphoid Structures in Pancreatic Cancer Patients Receiving Preoperative Chemotherapy 癌と化學療法 Volume 48, Issue 4, 465 - 471 (2021)• 酪酸菌 "Clostridium butyricum" MIYAIRI 588(CBM 588)透過調節腸道菌群以提升轉移性腎細胞癌患者之免疫治療臨床治療效果Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trialNature Medicine , VOL 28, April 2022, 704–712• 酪酸菌 "Clostridium butyricum" MIYAIRI 588(CBM 588) 改善牙周病引起的腸道疾病及類腸躁症之症狀The Intermucosal Connection between the Mouth and Gut in Commensal Pathobiont-Driven Colitis Cell, Volume 182, Issue 2, 23 July 2020, Pages 447-462.e14